On Oct 23, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $7 to $13.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $7.
Wells Fargo analyst Yanan Zhu maintains with a buy rating, and sets the target price at $9.
Baird analyst Jack Allen maintains with a buy rating, and adjusts the target price from $18 to $10.
Oppenheimer analyst Jay Olson maintains with a hold rating, and adjusts the target price from $12 to $10.
Truist Financial analyst Joon Lee maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The decision by Editas Medicine to shift focus to in vivo SCD approach and consider partnerships for reni-cel is seen as a potentially more strategic utilization of its knowledge and resources to generate value, following preclinical successes in in vivo editing of HSPCs.
Editas Medicine has shared preliminary results from its in vivo approach which focuses on using targeted lipid nanoparticle delivery to modify hematopoietic stem cells with the CRISPR-Cas12a enzyme. Simultaneously, the company has expressed an intent to form global partnerships for reni-cel, aiming to concentrate its resources on in vivo programs. Despite the promising early in vivo data, it is anticipated that investors may find it challenging to place significant value on a platform that is at such an early stage of development.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月23日，多家華爾街大行更新了$Editas Medicine (EDIT.US)$的評級，目標價介於7美元至13美元。
摩根士丹利分析師Terence Flynn維持持有評級，維持目標價7美元。
富國集團分析師Yanan Zhu維持買入評級，目標價9美元。
貝雅分析師Jack Allen維持買入評級，並將目標價從18美元下調至10美元。
奧本海默控股分析師Jay Olson維持持有評級，並將目標價從12美元下調至10美元。
儲億銀行分析師Joon Lee維持買入評級。
此外，綜合報道，$Editas Medicine (EDIT.US)$近期主要分析師觀點如下：
編輯醫藥決定將重點轉向體內SCD方法，並考慮與reni-cel合作伙伴關係，被視爲更具戰略意義地利用其知識和資源以實現價值的潛在途徑，在體內編輯HSPCs的臨床前成功後。
編輯醫藥公司已經分享了其體內方法的初步結果，該方法側重於使用靶向脂質納米顆粒遞送來修改CRISPR-Cas12a酶的造血幹細胞。同時，該公司表示意圖與全球夥伴建立夥伴關係，旨在集中其資源用於體內項目。儘管最初的體內數據令人鼓舞，但預計投資者可能會發現很難對這樣一個處於早期開發階段的平台賦予重大價值。
以下爲今日7位分析師對$Editas Medicine (EDIT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
